Initial postmarketing experience with Crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation

Anne Michelle Ruha, Steven C. Curry, Michael Beuhler, Ken Katz, Daniel E. Brooks, Kimberlie A. Graeme, Kevin Wallace, Richard Gerkin, Frank LoVecchio, Paul Wax, Brad Selden

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Study objective: We describe our postmarketing experience with patients receiving Crotalidae polyvalent immune Fab (CroFab; FabAV) antivenom for treatment of rattlesnake envenomation. Methods: The charts of 28 patients admitted between March 1 and September 9, 2001, with rattlesnake envenomation and treated with FabAV were reviewed for demographic information, time until antivenom treatment, laboratory findings, evidence of hypersensitivity reaction, length of hospital stay, and readmission to the hospital. Results: All patients had swelling, 20 patients had elevated prothrombin times (>14 seconds), 12 patients had low fibrinogen levels (<170 mg/dL), and 6 patients had thrombocytopenia (platelet count <120,000/mm3) on presentation. The total dose of FabAV ranged from 10 to 47 vials per patient. Hypofibrinogenemia was resistant to FabAV in some patients. On follow-up, recurrence of coagulopathy was detected in 3 patients, and recurrence of thrombocytopenia was detected in 1 patient. Two patients demonstrated delayed-onset severe thrombocytopenia. Recurrence or delayed-onset toxicity might have been underestimated because of incomplete follow-up in some patients. No acute hypersensitivity reactions occurred. Two patients reported mild symptoms of possible serum sickness on follow-up. Conclusion: FabAV effectively controlled the effects of envenomation; however, initial control of coagulopathy was difficult to achieve in some cases, and recurrence or delayed-onset hematotoxicity was common. When initially managing hematotoxicity, a trend toward normalization of laboratory values might be a more reasonable end point for FabAV treatment than attainment of normal reference values in nonbleeding patients.

Original languageEnglish (US)
Pages (from-to)609-615
Number of pages7
JournalAnnals of Emergency Medicine
Volume39
Issue number6
DOIs
StatePublished - 2002

Fingerprint

Crotalus
Therapeutics
Thrombocytopenia
Antivenins
Recurrence
Crotalidae Polyvalent immune Fab
Length of Stay
Hypersensitivity
Reference Values
Serum Sickness
Patient Readmission
Prothrombin Time
Platelet Count

ASJC Scopus subject areas

  • Emergency Medicine

Cite this

Ruha, A. M., Curry, S. C., Beuhler, M., Katz, K., Brooks, D. E., Graeme, K. A., ... Selden, B. (2002). Initial postmarketing experience with Crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation. Annals of Emergency Medicine, 39(6), 609-615. https://doi.org/10.1067/mem.2002.123698

Initial postmarketing experience with Crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation. / Ruha, Anne Michelle; Curry, Steven C.; Beuhler, Michael; Katz, Ken; Brooks, Daniel E.; Graeme, Kimberlie A.; Wallace, Kevin; Gerkin, Richard; LoVecchio, Frank; Wax, Paul; Selden, Brad.

In: Annals of Emergency Medicine, Vol. 39, No. 6, 2002, p. 609-615.

Research output: Contribution to journalArticle

Ruha, AM, Curry, SC, Beuhler, M, Katz, K, Brooks, DE, Graeme, KA, Wallace, K, Gerkin, R, LoVecchio, F, Wax, P & Selden, B 2002, 'Initial postmarketing experience with Crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation', Annals of Emergency Medicine, vol. 39, no. 6, pp. 609-615. https://doi.org/10.1067/mem.2002.123698
Ruha, Anne Michelle ; Curry, Steven C. ; Beuhler, Michael ; Katz, Ken ; Brooks, Daniel E. ; Graeme, Kimberlie A. ; Wallace, Kevin ; Gerkin, Richard ; LoVecchio, Frank ; Wax, Paul ; Selden, Brad. / Initial postmarketing experience with Crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation. In: Annals of Emergency Medicine. 2002 ; Vol. 39, No. 6. pp. 609-615.
@article{21514e50b01f418198a5f7d0a08625c2,
title = "Initial postmarketing experience with Crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation",
abstract = "Study objective: We describe our postmarketing experience with patients receiving Crotalidae polyvalent immune Fab (CroFab; FabAV) antivenom for treatment of rattlesnake envenomation. Methods: The charts of 28 patients admitted between March 1 and September 9, 2001, with rattlesnake envenomation and treated with FabAV were reviewed for demographic information, time until antivenom treatment, laboratory findings, evidence of hypersensitivity reaction, length of hospital stay, and readmission to the hospital. Results: All patients had swelling, 20 patients had elevated prothrombin times (>14 seconds), 12 patients had low fibrinogen levels (<170 mg/dL), and 6 patients had thrombocytopenia (platelet count <120,000/mm3) on presentation. The total dose of FabAV ranged from 10 to 47 vials per patient. Hypofibrinogenemia was resistant to FabAV in some patients. On follow-up, recurrence of coagulopathy was detected in 3 patients, and recurrence of thrombocytopenia was detected in 1 patient. Two patients demonstrated delayed-onset severe thrombocytopenia. Recurrence or delayed-onset toxicity might have been underestimated because of incomplete follow-up in some patients. No acute hypersensitivity reactions occurred. Two patients reported mild symptoms of possible serum sickness on follow-up. Conclusion: FabAV effectively controlled the effects of envenomation; however, initial control of coagulopathy was difficult to achieve in some cases, and recurrence or delayed-onset hematotoxicity was common. When initially managing hematotoxicity, a trend toward normalization of laboratory values might be a more reasonable end point for FabAV treatment than attainment of normal reference values in nonbleeding patients.",
author = "Ruha, {Anne Michelle} and Curry, {Steven C.} and Michael Beuhler and Ken Katz and Brooks, {Daniel E.} and Graeme, {Kimberlie A.} and Kevin Wallace and Richard Gerkin and Frank LoVecchio and Paul Wax and Brad Selden",
year = "2002",
doi = "10.1067/mem.2002.123698",
language = "English (US)",
volume = "39",
pages = "609--615",
journal = "Annals of Emergency Medicine",
issn = "0196-0644",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Initial postmarketing experience with Crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation

AU - Ruha, Anne Michelle

AU - Curry, Steven C.

AU - Beuhler, Michael

AU - Katz, Ken

AU - Brooks, Daniel E.

AU - Graeme, Kimberlie A.

AU - Wallace, Kevin

AU - Gerkin, Richard

AU - LoVecchio, Frank

AU - Wax, Paul

AU - Selden, Brad

PY - 2002

Y1 - 2002

N2 - Study objective: We describe our postmarketing experience with patients receiving Crotalidae polyvalent immune Fab (CroFab; FabAV) antivenom for treatment of rattlesnake envenomation. Methods: The charts of 28 patients admitted between March 1 and September 9, 2001, with rattlesnake envenomation and treated with FabAV were reviewed for demographic information, time until antivenom treatment, laboratory findings, evidence of hypersensitivity reaction, length of hospital stay, and readmission to the hospital. Results: All patients had swelling, 20 patients had elevated prothrombin times (>14 seconds), 12 patients had low fibrinogen levels (<170 mg/dL), and 6 patients had thrombocytopenia (platelet count <120,000/mm3) on presentation. The total dose of FabAV ranged from 10 to 47 vials per patient. Hypofibrinogenemia was resistant to FabAV in some patients. On follow-up, recurrence of coagulopathy was detected in 3 patients, and recurrence of thrombocytopenia was detected in 1 patient. Two patients demonstrated delayed-onset severe thrombocytopenia. Recurrence or delayed-onset toxicity might have been underestimated because of incomplete follow-up in some patients. No acute hypersensitivity reactions occurred. Two patients reported mild symptoms of possible serum sickness on follow-up. Conclusion: FabAV effectively controlled the effects of envenomation; however, initial control of coagulopathy was difficult to achieve in some cases, and recurrence or delayed-onset hematotoxicity was common. When initially managing hematotoxicity, a trend toward normalization of laboratory values might be a more reasonable end point for FabAV treatment than attainment of normal reference values in nonbleeding patients.

AB - Study objective: We describe our postmarketing experience with patients receiving Crotalidae polyvalent immune Fab (CroFab; FabAV) antivenom for treatment of rattlesnake envenomation. Methods: The charts of 28 patients admitted between March 1 and September 9, 2001, with rattlesnake envenomation and treated with FabAV were reviewed for demographic information, time until antivenom treatment, laboratory findings, evidence of hypersensitivity reaction, length of hospital stay, and readmission to the hospital. Results: All patients had swelling, 20 patients had elevated prothrombin times (>14 seconds), 12 patients had low fibrinogen levels (<170 mg/dL), and 6 patients had thrombocytopenia (platelet count <120,000/mm3) on presentation. The total dose of FabAV ranged from 10 to 47 vials per patient. Hypofibrinogenemia was resistant to FabAV in some patients. On follow-up, recurrence of coagulopathy was detected in 3 patients, and recurrence of thrombocytopenia was detected in 1 patient. Two patients demonstrated delayed-onset severe thrombocytopenia. Recurrence or delayed-onset toxicity might have been underestimated because of incomplete follow-up in some patients. No acute hypersensitivity reactions occurred. Two patients reported mild symptoms of possible serum sickness on follow-up. Conclusion: FabAV effectively controlled the effects of envenomation; however, initial control of coagulopathy was difficult to achieve in some cases, and recurrence or delayed-onset hematotoxicity was common. When initially managing hematotoxicity, a trend toward normalization of laboratory values might be a more reasonable end point for FabAV treatment than attainment of normal reference values in nonbleeding patients.

UR - http://www.scopus.com/inward/record.url?scp=18444407166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18444407166&partnerID=8YFLogxK

U2 - 10.1067/mem.2002.123698

DO - 10.1067/mem.2002.123698

M3 - Article

C2 - 12023703

AN - SCOPUS:18444407166

VL - 39

SP - 609

EP - 615

JO - Annals of Emergency Medicine

JF - Annals of Emergency Medicine

SN - 0196-0644

IS - 6

ER -